Search hospitals

>

Illinois

>

Evanston

NorthShore University HealthSystem-Evanston Hospital

Claim this profile

Evanston, Illinois 60201

Global Leader in Lung Cancer

Global Leader in Breast Cancer

Conducts research for Cancer

Conducts research for Ovarian Cancer

Conducts research for Prostate Cancer

315 reported clinical trials

19 medical researchers

Photo of NorthShore University HealthSystem-Evanston Hospital in EvanstonPhoto of NorthShore University HealthSystem-Evanston Hospital in EvanstonPhoto of NorthShore University HealthSystem-Evanston Hospital in Evanston

Summary

NorthShore University HealthSystem-Evanston Hospital is a medical facility located in Evanston, Illinois. This center is recognized for care of Lung Cancer, Breast Cancer, Cancer, Ovarian Cancer, Prostate Cancer and other specialties. NorthShore University HealthSystem-Evanston Hospital is involved with conducting 315 clinical trials across 433 conditions. There are 19 research doctors associated with this hospital, such as Christopher R. Trevino, Mary T Jenkins Vogel, MD, Bruce E. Brockstein, and Poornima Saha.

Area of expertise

1

Lung Cancer

Global Leader

NorthShore University HealthSystem-Evanston Hospital has run 49 trials for Lung Cancer. Some of their research focus areas include:

Stage IV
Stage II
Stage I
2

Breast Cancer

Global Leader

NorthShore University HealthSystem-Evanston Hospital has run 42 trials for Breast Cancer. Some of their research focus areas include:

ER positive
HER2 negative
Stage II

Top PIs

Clinical Trials running at NorthShore University HealthSystem-Evanston Hospital

Ovarian Cancer

Breast Cancer

Cancer

Prostate Cancer

Lung Cancer

Breast cancer

Bladder Cancer

Acute Myeloid Leukemia

Non-Small Cell Lung Cancer

Esophageal cancer

Image of trial facility.

Biobank Collection

for Cancer

This trial collects multiple tissue and blood samples, along with medical information, from cancer patients. The "Cancer Moonshot Biobank" is a longitudinal study. This means it collects and stores samples and information over time, throughout the course of a patient's cancer treatment. By looking at samples and information collected from the same people over time, researchers hope to better understand how cancer changes over time and over the course of medical treatments.

Recruiting

1 award

N/A

10 criteria

Image of trial facility.

Selumetinib + Olaparib

for Ovarian and Endometrial Cancer

This phase II ComboMATCH treatment trial compares selumetinib plus olaparib to selumetinib alone in women with endometrial or ovarian (fallopian tube and primary peritoneal) cancer that has come back (recurrent) or that remains despite treatment (persistent) and harbors a mutation in the RAS pathway. Selumetinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Olaparib is an inhibitor of PARP, an enzyme that helps repair deoxyribonucleic acid (DNA) when it becomes damaged. Blocking PARP may help keep tumor cells from repairing their damaged DNA, causing them to die. PARP inhibitors are a type of targeted therapy. The addition of olaparib to selumetinib could increase the percentage of tumors that shrink as well as lengthen the time that the tumors remain stable (without progression) as compared to selumetinib alone.

Recruiting

1 award

Phase 2

Image of trial facility.

Targeted Therapy

for Solid Tumors

This ComboMATCH patient screening trial is the gateway to a coordinated set of clinical trials to study cancer treatment directed by genetic testing. Patients with solid tumors that have spread to nearby tissue or lymph nodes (locally advanced) or have spread to other places in the body (advanced) and have progressed on at least one line of standard systemic therapy or have no standard treatment that has been shown to prolong overall survival may be candidates for these trials. Genetic tests look at the unique genetic material (genes) of patients' tumor cells. Patients with some genetic changes or abnormalities (mutations) may benefit from treatment that targets that particular genetic mutation. ComboMATCH is designed to match patients to a treatment that may work to control their tumor and may help doctors plan better treatment for patients with locally advanced or advanced solid tumors.

Recruiting

1 award

Phase 2

17 criteria

Similar Hospitals nearby

Frequently asked questions

What kind of research happens at NorthShore University HealthSystem-Evanston Hospital?

Where is NorthShore University HealthSystem-Evanston Hospital located?

Who should I call to ask about financial aid or insurance network?

What insurance does NorthShore University HealthSystem-Evanston Hospital accept?

What awards or recognition has NorthShore University HealthSystem-Evanston Hospital received?